Skip to main
INKT

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics is rated as a Buy with a price target of $35 based on a discounted cash flow analysis, a 14% discount rate, and a terminal growth rate of 0%. This valuation assumes value for their lead product agenT-797 for gastric cancer with a 20% probability of success, and does not include potential value from other pipeline assets or indications. However, there are risks to achieving this price target, such as safety concerns, lower than expected efficacy, commercial competition, regulatory issues, financing requirements, potential de-listing if share prices fall, and intellectual property protection.

Bears say

MiNK Therapeutics is facing significant risks in achieving their current price target, given the potential for safety concerns or lower efficacy in their clinical programs, as well as potential regulatory hurdles and competition in the market. Additionally, with a lack of inclusion of other pipeline assets or indications in their valuation, there is also a potential for their DCF analysis to be overly optimistic.

MiNK Therapeutics (INKT) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Strong Buy based on their latest research and market trends.

According to 1 analysts, MiNK Therapeutics (INKT) has a Strong Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.